BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4+ Th1 responses

Summary: High-risk non-muscle-invasive bladder cancer (NMIBC) is treated with intravesical instillations of Bacillus Calmette-Guérin (BCG), which trigger a local immune response. Improved patient outcomes have been linked to the recruitment of CD4+ T helper type 1 (Th1) cells to the bladder. However...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Paul Rollin, Benjamin Pluskwa, Emilie Artru, Tristan Le Vaslot, Daria Kartasheva-Ebertz, Diane Biron, Margaux Bossis, Fanny Onodi, Joel LeMaoult, Nathalie Rouas-Freiss, Mathieu F. Chevalier, Cecilia S. Lindestam Arlehamn, Alessandro Sette, Alexandra Masson-Lecomte, François Desgrandchamps, Evanguelos Xylinas, Pierre Tonnerre
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-02-01
Serija:	iScience
Teme:	immunology oncology therapeutics immune response
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2589004226000519
Oznake:	Označite Brez oznak, prvi označite!